Recent developments highlight clinical progress, corporate governance enhancements, and capital management activities.

• Glucotrack announced successful repurchase of over 90% of Series A warrants as part of its capital formation strategy [N2].
• The company's investigational continuous glucose monitor showed accuracy in a first-in-human study completed in 2025 [N3].
• Dr. Victoria E. Carr-Brendel was appointed to the Board of Directors in 2025 [N4].
• A patient advisory board was formed to enhance development of the continuous blood glucose monitor [N5].
• Glucotrack advanced its continuous blood glucose monitoring technology with clinical study initiation in Australia by Q3 2025 [N6].
• First-in-human results of the continuous blood glucose monitor were presented at the 2025 ATTD conference [N7][N8].
• The company plans to present at the TechBio Showcase 2025 [N1].

Glucotrack's implantable continuous blood glucose monitor technology offers potential improvements in accuracy, convenience, and implant longevity compared to existing CGM devices. Successful clinical trials and regulatory approvals could enable the company to address unmet needs in diabetes management, particularly for patients requiring continuous monitoring with minimal device burden. The company's ISO 13485 certification and experienced management team support its development and manufacturing capabilities. Recent clinical progress, including first-in-human studies and planned U.S. trials, demonstrate advancing execution milestones. The formation of a patient advisory board and collaborations with clinical investigators may enhance product development and adoption strategies.

Glucotrack faces significant risks including the need for successful completion of extensive and costly clinical trials and regulatory approvals before commercialization. The company has a history of operating losses, limited liquidity, and an accumulated deficit, raising concerns about its ability to continue as a going concern without additional capital. Manufacturing depends on third-party contract manufacturers subject to regulatory inspections and quality risks. The company competes against established CGM manufacturers with greater resources and market presence. Material weaknesses in internal controls and Nasdaq listing compliance challenges add operational risks. Failure to obtain reimbursement coverage or to achieve market acceptance could adversely affect commercial viability.

Glucotrack's potential competitive advantages include its implantable continuous blood glucose monitor technology that measures glucose directly in the blood with effectively zero lag time, potentially offering improved accuracy and convenience over existing CGM devices that measure interstitial fluid glucose with lag and require frequent sensor replacement. The company's sensor longevity, supported by preclinical and modeling data indicating multi-year implant life, may provide a differentiation in usability and patient adherence. Additionally, the use of established implant procedures and device form factors common in cardiovascular implantable devices may facilitate adoption. However, the company faces significant competition from well-established CGM manufacturers with greater resources, brand recognition, and integrated insulin delivery systems. Glucotrack's technology is not yet approved for marketing and remains in clinical development, which limits current competitive positioning.

• Regulatory Approval Risk: Glucotrack's implantable CBGM is not yet approved for sale in the U.S. or other jurisdictions and requires successful completion of clinical trials and FDA approval, which are costly, time-consuming, and uncertain.
• Financial and Liquidity Risk: The company has incurred significant net losses and has limited cash reserves, raising substantial doubt about its ability to continue as a going concern without additional capital.
• Manufacturing Risk: Dependence on third-party contract manufacturers exposes the company to risks of production delays, quality control issues, and regulatory compliance challenges.
• Competitive Risk: Glucotrack faces intense competition from established CGM manufacturers with greater resources, brand recognition, and integrated product offerings.
• Operational and Control Risk: Material weaknesses in internal controls over financial reporting have been identified, and remediation efforts are ongoing but not guaranteed to be fully effective.
• Market Listing Risk: The company's common stock trades below Nasdaq minimum bid price requirements, and there is risk of delisting which could impact investor confidence and capital access.

• Glucotrack, Inc. is a Delaware medical device company focused on developing an implantable continuous blood glucose monitor (CBGM) for Type 1 and insulin-using Type 2 diabetes patients or those at risk for hypoglycemia.
• The company previously developed a non-invasive glucose monitor with CE Mark approval but ceased commercialization and development of that product by 2023 to focus on the implantable CBGM.
• The Glucotrack CBGM uses an intravascular approach with a subcutaneous implant connected to a lead placed directly into a blood vessel, enabling continuous blood glucose measurement with effectively zero lag time compared to interstitial fluid CGMs.
• Preclinical studies demonstrated sensor longevity of at least two years, with in vitro and in silico modeling supporting feasibility of three-year implant life.
• Multiple animal studies showed safety and accuracy of the sensor up to six months, and a 60-day preclinical study demonstrated continuous glucose sensing in the epidural space with good safety.
• The company completed a first-in-human acute study in 2025 with 8 in-hospital patients, meeting safety and performance endpoints, with results presented at major diabetes conferences.
• A long-term multicenter feasibility study in Australia was initiated in 2025 but was closed after early learnings and planned product updates led to reassessment; the company is focusing on a U.S. clinical trial program.
• Discussions with the U.S. FDA are ongoing, with an Investigational Device Exemption (IDE) submission planned for Q2 2026 and a U.S. clinical trial program anticipated in the second half of 2026, subject to FDA approval.
• The company holds ISO 13485:2016 certification for quality management systems relevant to medical device design and manufacturing, with successful annual audits and no major nonconformities.
• The executive management team includes CEO Paul V. Goode, with extensive medical device experience, and CFO Peter C. Wulff, with 40 years of financial leadership.
• The Board of Directors includes members with backgrounds at major diabetes and medical device companies such as Dexcom, Medtronic, and Abbott.
• Glucotrack faces competition from established CGM manufacturers like Abbott, Dexcom, and Medtronic, which have greater resources, brand recognition, and integrated insulin delivery systems.
• The company has incurred net losses since inception, with a net loss of approximately $19.4 million for the year ended December 31, 2025, and an accumulated deficit of about $151.8 million as of that date.
• As of December 31, 2025, Glucotrack had cash and cash equivalents of $7.4 million and a current ratio of 1.61, indicating moderate liquidity.
• The company completed a private placement in late 2025 raising approximately $4.0 million in gross proceeds to support operations.
• Glucotrack has repurchased over 90% of its Series A warrants as part of a capital formation strategy.
• The company formed a patient advisory board to enhance development of its continuous blood glucose monitor.
• Glucotrack is advancing clinical studies, including initiating a clinical study in Australia in 2025 and planning U.S. trials.
• The company presented first-in-human results of its continuous blood glucose monitor at the 2025 ATTD conference and the American Diabetes Association annual meeting.
• Glucotrack appointed Dr. Victoria E. Carr-Brendel to its Board of Directors in 2025.
• The company is preparing for an IDE submission to the FDA in Q2 2026 and collaborating with a respected physician investigator and medical institution for U.S. clinical studies.
• Glucotrack's technology aims to improve accuracy, convenience, and implant longevity compared to existing CGM devices, which typically measure glucose in interstitial fluid and require frequent sensor replacement.
• The company is not yet generating material revenue and continues to invest in research and development and clinical trials.
• Glucotrack's first-generation non-invasive product was withdrawn from the market and is no longer being developed.
• The company is subject to regulatory risks, including the need for FDA and other approvals before commercialization.
• Glucotrack faces risks related to manufacturing, relying on third-party contract manufacturers who must comply with quality standards and regulatory inspections.
• The company has identified material weaknesses in internal controls over financial reporting and is implementing remediation measures.
• Glucotrack's common stock trades below $1.00 per share and has faced Nasdaq listing compliance challenges, including a reverse stock split and ongoing monitoring.
• The company is exposed to risks related to intellectual property protection, competition, regulatory approval, and capital raising.
• Glucotrack's clinical development program includes plans to address product improvements and protocol modifications based on early clinical study learnings.